RecruitingPhase 1 / Phase 2NCT07038343
Oncology
Nasopharyngeal carcinoma
188
studies recruiting now
as of 7 Sept 2026
1,129
studies registered in total
as of 7 Sept 2026
8
countries with a recruiting site
as of 7 Sept 2026
4 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT06064097
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
RecruitingPhase 2NCT06029270
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
RecruitingPhase 1NCT07625423
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
RecruitingPhase 2NCT06980038
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 188 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Nasopharyngeal carcinoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Nasopharyngeal carcinoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (NFKBIA).
Treatments being studied
2 approved treatments and 69 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Lotilaner (Adtab (previously lotilaner elanco))Approved: Toripalimab (Loqtorzi)
Phase 3Cadonilimab
Phase 3Cisplatin (Cisplatin)
Phase 3Nimotuzumab
Phase 3Epirubicin
Phase 3Penpulimab
Phase 3Rivoceranib
Phase 3Gemcitabine (Gemzar)
Phase 3Celecoxib (Celebra)
+ 61 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).